A Phase 1 interventional study of Umbilical or placental derived mesenchymal stem cells in Cerebral Palsy, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Withdrawn at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment
Duplicate registration; study is registered and actively tracked under NCT05018819. No participants were enrolled under this record.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 372 studies in Cerebral Palsy with a site in United States — 74 open to participants now, 102 under way, none of them phase 3. Cerebral Palsy · United States.
Among the 372 studies in Cerebral Palsy with a site in United States, this one is the 283rd largest by enrollment of the 296 interventional ones that give a count, is one of 24 that started in 2026, is one of 25 in phase 1, and was the 237th registered.
1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.
Browse Cerebral Palsy studies →74 of the 372 studies in Cerebral Palsy with a site in United States are open now. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 4–65
University of Wisconsin, Madison · Sites in United States
Ages 7–17
Columbia University · Sites in United States
Ages 18–80
Martin Piazza · Sites in United States
Ages 3–14
National Institutes of Health Clinical Center (CC) · Sites in United States
Ages 5–25
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
372 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 31 · Phase 3 18 · Phase 4 7
First in 1987; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 25 across the 296 interventional studies, 61 across the 71 observational. Of the 226 that completed or were terminated, 83 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 372 have an industry lead sponsor. The 10 most frequent:
The Foundation for Orthopaedics and Regenerative Medicine is the lead sponsor of 33 studies on the registry; 19 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
The Foundation for Orthopaedics and Regenerative Medicine has 2 studies filed under Cerebral Palsy — fewer than ten, so there is no comparison to draw.
24 of the studies in Cerebral Palsy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07516067Martin PiazzaSpinal Cord Stimulation for Children With Cerebral Palsy | 2026-11 |
| NCT05339932Grand Valley State UniversityGrand Valley State University (GVSU) Skills on Wheels | 2026-11-30 |
| NCT06377085Shirley Ryan AbilityLabRepurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy | 2026-12 |
| NCT04897347Teachers College, Columbia UniversityRobotic TruST-Postural Intervention for Children With Cerebral Palsy | 2026-12 |
| NCT03937700Shirley Ryan AbilityLabRobot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker | 2026-12-01 |
Add all 24 to your calendar (.ics) → With an account.
Among the 372 studies in Cerebral Palsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial will study the safety and efficacy of intravenous infusion of cultured umbilical or placental derived mesenchymal stem cells for the treatment of Cerebral Palsy
Studies have shown that stem cell treatment is safe and efficacious for the treatment of Cerebral Palsy (CP). This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured umbilical or placental derived mesenchymal stem cells for the treatment of CP. Patients with CP will receive a single intravenous infusion of MSCs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intravenous infusion of 100 million cells
Biological: Umbilical or placental derived mesenchymal stem cells
Umbilical or placental derived mesenchymal stem cells
Safety (adverse events)
Clinical monitoring of possible adverse events or complications
Time frame: Four year follow-up
Efficacy: Gross Motor Function Measure (GMFM)
It will be completed for each follow up point
Time frame: Four year follow-up
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Dec 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Duplicate registration; study is registered and actively tracked under NCT05018819. No participants were enrolled under this record.
Duplicate registration; study is registered and actively tracked under NCT05018819. No participants were enrolled under this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Foundation for Orthopaedics and Regenerative Medicine